Cargando…
A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
INTRODUCTION: About one-third of primary biliary cholangitis (PBC) patients do not exhibit complete response to ursodeoxycholic acid (UDCA). Some of these patients were reported to benefit from the combination therapy of fibrates and UDCA, but more clinical evidence is required. In this study, we co...
Autores principales: | Li, Chunlei, Zheng, Kunyu, Chen, Yiran, He, Chengmei, Liu, Suying, Yang, Yunjiao, Li, Mengtao, Zeng, Xiaofeng, Wang, Li, Zhang, Fengchun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340330/ https://www.ncbi.nlm.nih.gov/pubmed/35924008 http://dx.doi.org/10.1177/20406223221114198 |
Ejemplares similares
-
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
por: Ding, Dawei, et al.
Publicado: (2022) -
Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020) -
Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis
por: Zhang, Yan, et al.
Publicado: (2015) -
Animal models of primary biliary cholangitis: status and challenges
por: Wang, Xu, et al.
Publicado: (2023) -
Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease
por: Cortez‐Pinto, Helena, et al.
Publicado: (2021)